Ken Griffin Exact Sciences Corp Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$42.43 - $70.83 $1.79 Million - $2.98 Million	42,100 Added 17.79%	278,700 $19 Million
Q2 2024 Aug 14, 2024	BUY	$41.33 - $74.26 $5.24 Million - $9.41 Million	126,700 Added 115.29%	236,600 $10 Million
Q1 2024 May 15, 2024	BUY	$56.27 - $73.77 $281,350 - $368,850	5,000 Added 4.77%	109,900 $7.59 Million
Q4 2023 Feb 14, 2024	BUY	$59.06 - $75.72 $1.69 Million - $2.17 Million	28,600 Added 37.48%	104,900 $7.76 Million
Q3 2023 Nov 14, 2023	SELL	$65.94 - $99.04 $1.37 Million - $2.06 Million	-20,800 Reduced 21.42%	76,300 $5.21 Million
Q2 2023 Aug 14, 2023	BUY	$62.68 - $95.05 $908,860 - $1.38 Million	14,500 Added 17.55%	97,100 $9.12 Million
Q1 2023 May 15, 2023	SELL	$47.19 - $70.77 $8.21 Million - $12.3 Million	-173,900 Reduced 67.8%	82,600 $5.6 Million
Q4 2022 Feb 14, 2023	BUY	$30.35 - $53.15 $525,055 - $919,495	17,300 Added 7.23%	256,500 $12.7 Million
Q3 2022 Nov 14, 2022	BUY	$31.97 - $49.37 $885,569 - $1.37 Million	27,700 Added 13.1%	239,200 $7.77 Million

674

163M

2.58M

2.19M

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $10.9B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.